Health

Dear Patients, Family Members, and Friends, Summer is the perfect time to slow down, reconnect, and celebrate the community that makes The Vancouver Thalassemia Society of BC so special — and this year’s Annual Summer Picnic is shaping up to be our best one yet.

This special evening will feature presentations and updates from Dr. Kevin Kuo and Josie Sirna from the Thalassemia Foundation of Canada (TFC). It’s a wonderful opportunity to hear the latest medical information, ask questions, and connect with other patients and families in our community.

We are excited to invite you to our upcoming Patient Education Night on Thursday, September 25th, at St. Paul’s Hospital.

The Vancouver Thalassemia Society of BC is delighted to invite you to our Annual Summer Picnic — a perfect opportunity to relax, enjoy great food, and spend quality time with friends and family. 📅 Event Details Whether you’re a long-time member or new to our community, this picnic is

On May 8, 2025, the global thalassaemia community will come together to celebrate International Thalassaemia Day. This year, we proudly embrace the theme, “Together for Thalassaemia: Uniting Communities, Prioritizing Patients”, and rally under the powerful slogans “#WeAre1“ and “PatientsFirst“. Every year on 8 May, iconic monuments and buildings around the

For someone like me, living with thalassemia major, regular blood transfusions every 21 days since I was 1 year old have been my lifeline and a reminder to be grateful. Growing up with the belief that my life might be short, due to these donations

Abstract BACKGROUND Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis through ex vivo clustered regularly interspaced short palindromic repeats (CRISPR)–Cas9 gene editing of the erythroid-specific enhancer region of BCL11A in autologous CD34+ hematopoietic stem and progenitor cells (HSPCs). METHODS We conducted

GENE-EDITING TREATMENT APPROVED BY HEALTH CANADA FOR SICKLE CELL DISEASE AND THALASSEMIA WAS TESTED IN ST. PAUL’S HOSPITAL CLINICAL TRIAL A gene editing treatment for sickle-cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT) has received marketing authorization from Health Canada, following the results of a first-in-Canada

#SaveTheDate – The 1st TIF Pan American Conference on Thalassaemia & Other Haemoglobin Disorders & the 2nd RAIN Summit are coming to Washington D.C.! 🗓️ 11 – 13 July 2025 📍 Hyatt Regency Crystal City, Washington D.C., US 🗣️ In-person attendance only This landmark event,